Robinhood is launching a new feature that lets users create dedicated accounts for AI agents to autonomously buy and sell stocks. The brokerage says the tool automates investment decisions, though it carries significant financial risk.
Robinhood announced Wednesday that traders can now set up separate accounts funded with specific amounts of capital for AI agents to manage. The agents can execute trades across the market without manual intervention.
The company frames the feature as an automation tool for common investment tasks. Potential uses include having an agent monitor specific industries and execute trades based on predetermined criteria, or automatically rebalancing existing portfolios.
However, Robinhood included a prominent warning alongside the announcement. The feature carries substantial risk—AI agents could execute losing trades at scale, potentially depleting accounts quickly. Users retain responsibility for their agents' trading decisions and resulting losses.
The move reflects broader adoption of AI agents in financial services. Unlike chatbots that provide information, these agents take independent action within defined parameters. Robinhood's implementation requires users to explicitly fund accounts and set boundaries, giving traders some control over exposure.
The feature also reportedly extends to credit card purchases, allowing AI agents to make transactions beyond stock trading. This expansion of agent capabilities further increases the potential for both gains and losses.
Robinhood's AI agent feature arrives as fintech platforms compete to integrate AI tools into their products. The brokerage positions the capability as a convenience for active traders, though it introduces new considerations around automation risk and financial decision-making.
Customers interested in testing the feature can create a dedicated agent account through Robinhood's platform.
Open-weight AI companies—those releasing freely available models—are attracting major acquisition interest from tech giants. The trend reflects growing capital investment in the business model of distributing AI models at no cost.
Google Deepmind has upgraded its Co-Scientist AI system to autonomously plan experiments, operate lab equipment, and publish scientific papers. The Gemini-based multi-agent platform demonstrated experimentally validated results across materials science, chemistry, and medical AI development.
Uber's weekly AI agent requests have grown nearly tenfold since February, yet the company has held spending flat since April after exhausting its entire 2026 AI budget in Q1.
A recent paper shows artificial intelligence often diagnoses and treats patients better than human physicians. The findings are prompting difficult conversations within the medical community about the profession's evolving role.